Hemab Therapeutics Holdings, Inc.
corporate_fare Company Profile
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for COAG at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for COAG spans 8-K, 10-Q, SCHEDULE 13D, 4.
Recent high-impact activity:
- Hemab Posts $27.3M Q3 Loss, Starts Pivotal SOLARA Phase 3 in Glanzmann Thrombasthenia
- Sutacimig Cuts Prothrombin Time Over 50% After Single Dose in Two Patients
- Hemab Doses First Patient in Phase 1 Trial of HMB-003 for Heavy Menstrual Bleeding
- Hemab Posts Q2 Loss, Extends Cash Runway to 2029, but Flags Unremediated Material Weaknesses
- Hemab Posts Q2 Loss of $24.2M, Gets FDA Nod for Phase 3 Trial
Short Interest & Short Volume
7.31 days to coverFINRA reported short interest of 3,305,474 shares in COAG as of the October 30, 2026 settlement, a 4.6% increase from the prior period — about 7.3 days to cover at its recent average daily volume. On November 20, 2026, 86.3% of COAG volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.